Medical management of advanced gastric cancer

Cancer Treatment Reviews

Volumn 24, Issue 2, 1998, Pages 113-118

  Hill, M E ^a   Cunningham, D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; PACLITAXEL; SEMUSTINE; TRIAZINATE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE S PHASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; ORAL DRUG ADMINISTRATION; QUALITY OF LIFE; STOMACH CANCER;

EID: 0031661046     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(98)90077-9     Document Type: Article

References (52)

1. Dupont JB, Lee JR, Burton GR, Cohn I. Adenocarcinoma of the stomach: review of 1497 cases. Cancer 1978; 41: 941-953.
2. Whelan SL, Parkin DM, Masuyer E (ed) Trends in Cancer Incidence and Mortality, Scientific Publication no. 102. Lyon: IARC, 1993.
3. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990; 62: 440-443.
4. Allum WH, Powell DJ, McConkey CC, Fielding JW. Gastric cancer: a 25-year review. Br J Surg 1989; 76: 535-540.
5. Glimelius B, Hoffman K, Haglund U. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994; 5: 189-190.
6. Murad AM, Santigao FF, Petroianu et al. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
7. Pyrhönen S, Kuitunen T, Nyandoto P, Louri M. Randomised comparison of FEMTX plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-591.
8. Glimelius B, Huffman K, Graf W et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6: 267-274.
9. Glimelius B, Ekstrom K, Hoffman K et al. Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168.
10. Moynihan T, Henson R, Anderson T et al. Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 1988; 11: 461-464.
11. Comis R. Integration of chemotherapy into combined modality treatment of solid tumours. Cancer Treat Rev 1974; 1: 22-23.
12. Kolaric K, Potrebica V, Cevek J. Phase II clinical trial of 4′-epi-doxorubicin in metastatic solid tumours. J Cancer Res Clin Oncol 1983; 106: 148-152.
13. Scarffe JH, Kenny JB, Johnson RJ et al. Phase II trial of epirubicin in gastric cancer. Cancer Treat Rep 1985; 69: 1275-1277.
14. Cazap E, Bruno M, Levy D et al. Phase II trial of 4′-epi-doxorubicin in advanced gastric cancer. Proc Am Soc Clin Oncol 1986; 5: 91 (abstract 356).
15. Moertel CG & Levin PT. Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rev 1979; 63: 1863-1872.
16. Sulkes A, Smythe J, Sessa C et al. Docetaxel (Taxotere™) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 1994; 72: 380-383.
17. Futatsuki K, Wakui A, Nakao I et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 1994; 21: 1033-1038.
18. Leichman L & Berry BT. Cisplatin therapy for adenocarcinoma of the stomach. Semin Oncol 1991; 18 (Suppl. 3): 25-33.
19. Kovach JS, Moertel CG, Schutt AJ et al. A controlled study of combined 1,3-bis-(2 chloroethyl)-1-nitrosourea and 5-FU therapy for advanced gastric and pancreatic cancer. Cancer 1974; 33: 563-567.
20. Ajani JA, Fairweather J, Dumas P et al. A phase II study of Taxol® in patients with advanced untreated gastric carcinoma. Proc Am Soc Clin Oncol 1997; 16: 263a (abstract 933).
21. Bruckner H, Lokich J & Stablein D. Studies of Baker's antifol, methotrexate and razoxane in advanced gastric cancer: a Gastrointestinal Tumour Study Group report. Cancer Treat Rep 1982; 66: 1713-1717.
22. Moertel CG, Mittelman JA, Bakemeier RF et al. Sequential and combination chemotherapy of advanced gastric cancer. Cancer 1976; 38: 676-682.
23. O'Dwyer PJ, Leyland-Jones B, Alonso MT et al. Drug therapy: etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med 1985; 213: 692-701.
24. Enzig A, Kelson DP & Change E. Phase II trial of carboplatin in patients with adenocarcinomas of the upper gastrointestinal tract. Cancer Treat Rep 1985; 69: 1453-1454.
25. Christman K, Kelsen D, Saltz L, Tarassoff PG. Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 1994; 73: 5-7.
26. Baker LH, Talley RW, Matter R et al. A Southwest Oncology Group study. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. Cancer 1976; 38: 1-7.
27. Levi JA, Fox RM, Tattersall MH et al. Analysis of a pro-spectively randomised comparison of doxorubicin versus 5-FU, doxorubicin and BCNU in advanced gastric cancer: implications for future studies. L Clin Oncol 1986; 4: 1348-1355.
28. Schnitzler G, Quesser W, Heim ME et al. Phase III study of 5-FU and carmustine vs. 5-FU, carmustine and doxorubicin in advanced gastric cancer. Cancer Treat Rep 1986; 70: 477-479.
29. McDonald J, Schein PS, Woolley PV et al. 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980; 93: 533-536.
30. Douglass HO Jr, Lavin PT, Goudsmit A et al. An Eastern Co-operative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, adriamycin and 5-FU in advanced measurable gastric cancer (EST 2277). J Clin Oncol 1984; 2: 1372-1381.
31. Cullinan SA, Moertel CG, Fleming TR et al. A comparison of three chemotherapy therapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin and mitomycin. J Am Med Assoc 1985; 253: 2061-2067.
32. The Gastrointestinal Tumour Study Group. Triazinate and platinum efficacy in combination with 5-FU and doxorubicin: results of a 3-arm randomised trial in metastatic gastric cancer. J Natl Cancer Inst 1988; 80: 1011-1015.
33. Klein H, Wickramayake PD, Dieterle F et al. High dose MTX/ 5-FU and adriamycin for gastric cancer. Semin Oncol 1983; 10: 29-31.
34. Wils O, Klein H, Wagner D et al. Sequential high dose methotrexate and fluorouracil combined with doxorubicin: a step forward in the treatment of gastric cancer. J Clin Oncol 1991; 9: 827-831.
35. Preusser P, Wilke H, Achterrath W et al. Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989; 7: 1310-1317.
36. Wilke H, Preusser P, Fink U et al. Preoperative chemotherapy in locally advanced and non-resectable gastric cancer: a phase II study with etoposide, doxorubicin and cisplatin. J Clin Oncol 1989; 7: 1318-1326.
37. Kelson D, Atiq OT, Saltz L et al. FAMTX versus etoposide, doxorubicin and cisplatin: a randomised trial in gastric cancer. J Clin Oncol 1992; 10: 541-548.
38. Kim NK, Park YS, Heo DS et al. A phase III randomised study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin-C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-3818.
39. Coccini G, Bella M, Zironi S et al. Fluorouracil, doxorubicin and mitomycin-C versus FELV chemotherapy in advanced gastric cancer: A prospective randomised trial. Italian Oncology Group for Clinical Research. J Clin Oncol 1994; 12: 2687-2693.
40. Webb A, Cunningham D, Scarffe JH et al. A randomised trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced oesophago-gastric cancer. J Clin Oncol 1997; 15: 261-267.
41. Cullinan S, Moertel C, Wieand H et al. Controlled evaluation of three drug combinations versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 1994; 12: 412-416.
42. Findlay M, Cunningham D, Norman A et al. A phase II study in advanced gastric cancer using epirubicin and cisplatin in combination with continuous 5-FU (ECF). Ann Oncol 1994; 5: 609-616.
43. Zaniboni A, Barni S, Labianca R et al. Epirubicin, cisplatin and continuous infusion of 5-fluorouracil as an active and safe regimen for patients with advanced gastric cancer: an Italian Group Study of Digestive Tract Cancer (GISCAD) report. Cancer 1995; 76: 1694-1699.
44. Bamias A, Hill ME, Cunningham D et al. Epirubicin, cisplatin and protracted venous infusion of 5-fluorouracil for oesophago-gastric adenocarcinoma: response, toxicity, quality of life and survival. Cancer 1996; 76: 1978-1985.
45. Fraile RJ, Baker LH, Buroker TR et al. Pharmacokinetics of 5-FU administered orally, by rapid intravenous infusion and by slow infusion. Cancer Res 1980; 40: 2223-2228.
46. Eitenne MC, Bernard S, Fischel JL et al. Dose reduction without loss of efficacy of 5-FU and cisplatin combined with folinic acid: in vitro studies on human head and neck carcinoma cell lines. Br J Cancer 1991; 63: 372-377.
47. Cascinu S, Labianca R, Alessandroni P et al. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 1997; 15: 3313-3319.
48. Cohen JL, Irwin LE, Marshall GJ et al. Clinical pharmacology of oral and intravenous 5-FU. Cancer Chemother Rep 1974; 58: 723-731.
49. Heggie GD, Sommadossi J-P, Cross DS et al. Clinical pharmacokinetics of 5-FU and its metabolites in plasma, urine and bile. Cancer Res 1987; 47: 2203-2206.
50. Baker SD, Khor SP, Adjei AA et al. Pharmacokinetic, oral bio-availability and safety study of 5-FU in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996; 14: 3085-3096.
51. Shirao K, Yasuhiro S, Hitoshi K et al. Phase I/II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15: 921-927.
52. Sukuki T, Ochiai T, Nagata N et al. High dose chemotherapy with autologous bone marrow transplantation for the treatment of advanced gastric cancer. Cancer 1993; 72: 2537-2542.